CARsgen Therapeutics Holdings Limited (HKG:2171)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
23.10
-0.25 (-1.07%)
Jun 27, 2025, 4:08 PM HKT
367.61%
Market Cap 12.79B
Revenue (ttm) 41.95M
Net Income (ttm) -849.35M
Shares Out 553.46M
EPS (ttm) -1.54
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,239,400
Average Volume 3,653,470
Open 24.00
Previous Close 23.35
Day's Range 22.60 - 24.05
52-Week Range 2.48 - 25.60
Beta 0.48
RSI 58.76
Earnings Date Aug 22, 2025

About HKG:2171

CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China. Its products include CT053 for the treatment of relapsed/refractory multiple myeloma (R/R MM). The company is also developing autologous CAR-T product candidates, including CT041, which targets Claudin 18.2, is in phase II/III clinical trial for gastric/gastroesophageal junct... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 465
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2171
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.